1. Abigail, Ezekiel, and Freireich Mike Martin, MD My last Grand Rounds 12/19/8 2. CAVEAT 1:MY ROLE IN THIS PRESENTATION IS TO BE IMPARTIALCAVEAT 2:WITHOUT YOUR COMMENTS,…

Slide 1Personalised Cancer Medicine in Phase 1 Cancer Research at Rigshospitalet Ulrik Lassen MD, PH.D Phase 1 Unit Slide 2 Background New targeted therapy is selected according…

Slide 1 Optimal Sequence of Therapies for Advanced GI Neuroendocrine Tumors (NET) Tim Hobday M.D. Mayo Clinic Rochester, MN Tim Hobday M.D. Mayo Clinic Rochester, MN Slide…

Bevacizumab: Antiangiogenic therapy for breast cancer: where do we stand? Fortunato Ciardiello Division of Medical Oncology, Department of Clinical and Experimental Medicine,…

Best of ASCO in Gyn Oncology Adnan R Munkarah Biologics in Recurrent Ovarian Ca Cediranib- highly selective and potent oral TK inhibitor of VEGFR1, VEGFR2, VEGFR3 and c-Kit(Matulanis…

PowerPoint Presentation Program Goals Introduction Using Vaccines in the Treatment of NSCLC Vaccine Approach in NSCLC Targeting Tumor Antigens Vaccines Evaluated in Phase…

Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation…

Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome Eric Van Cutsem*, I. Lang, G. Folprecht,…

Best of ASCO in Gyn Oncology Adnan R Munkarah Biologics in Recurrent Ovarian Ca Cediranib- highly selective and potent oral TK inhibitor of VEGFR1, VEGFR2, VEGFR3 and c-Kit(Matulanis…

Other B-Cell Malignancies Mantle Cell Lymphoma MALT HIV-associated DLCL Burkitt’s Lymphoma Waldenstrom’s Macroglobulinemia Hodgkin’s Disease Autoimmune Disorders MabThera®…